The Effect of Testosterone Therapy on the Mortality Rate in Men Suffering From Diabetes Mellitus by Tran, Deion
Pacific University
CommonKnowledge
School of Physician Assistant Studies Theses, Dissertations and Capstone Projects
Summer 8-8-2015
The Effect of Testosterone Therapy on the
Mortality Rate in Men Suffering From Diabetes
Mellitus
Deion Tran
Follow this and additional works at: http://commons.pacificu.edu/pa
Part of the Medicine and Health Sciences Commons
This Capstone Project is brought to you for free and open access by the Theses, Dissertations and Capstone Projects at CommonKnowledge. It has
been accepted for inclusion in School of Physician Assistant Studies by an authorized administrator of CommonKnowledge. For more information,
please contact CommonKnowledge@pacificu.edu.
Recommended Citation
Tran, Deion, "The Effect of Testosterone Therapy on the Mortality Rate in Men Suffering From Diabetes Mellitus" (2015). School of
Physician Assistant Studies. Paper 547.
The Effect of Testosterone Therapy on the Mortality Rate in Men Suffering
From Diabetes Mellitus
Abstract
Background: Low testosterone level is common with aging men and is associated with many adverse
outcomes like diabetes mellitus (DM). In addition, men with low testosterone and DM have increased
mortality risk. This review looks at the effect of testosterone therapy on mortality in men suffering from DM.
Methods: An exhaustive literature search of available databases using Medline-OVID, CINAHL and Web of
Science was conducted using the following keywords: testosterone, diabetes mellitus, and mortality.
Results: The initial search of the databases yielded 58 articles. A total of two articles, both observation
studies, met the inclusion criteria. The articles demonstrated decreased mortality rate in treated men with low
testosterone suffering from DM.
Conclusion: In both observation studies, testosterone therapy is associated with decreased mortality rate in
men with DM. However, due to the studies’ limitations, further studies are needed to confirm the data.
Keywords: Testosterone, mortality, diabetes mellitus, therapy.
Degree Type
Capstone Project
Degree Name
Master of Science in Physician Assistant Studies
First Advisor
Saje Davis-Risen, PA-C, MS
Keywords
Testosterone, mortality, diabetes mellitus, therapy
Subject Categories
Medicine and Health Sciences
Rights
Terms of use for work posted in CommonKnowledge.
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/547
Copyright and terms of use
If you have downloaded this document directly from the web or from CommonKnowledge, see the
“Rights” section on the previous page for the terms of use.
If you have received this document through an interlibrary loan/document delivery service, the
following terms of use apply:
Copyright in this work is held by the author(s). You may download or print any portion of this document
for personal use only, or for any use that is allowed by fair use (Title 17, §107 U.S.C.). Except for personal
or fair use, you or your borrowing library may not reproduce, remix, republish, post, transmit, or
distribute this document, or any portion thereof, without the permission of the copyright owner. [Note:
If this document is licensed under a Creative Commons license (see “Rights” on the previous page)
which allows broader usage rights, your use is governed by the terms of that license.]
Inquiries regarding further use of these materials should be addressed to: CommonKnowledge Rights,
Pacific University Library, 2043 College Way, Forest Grove, OR 97116, (503) 352-7209. Email inquiries
may be directed to:. copyright@pacificu.edu
This capstone project is available at CommonKnowledge: http://commons.pacificu.edu/pa/547
 
 
NOTICE TO READERS 
 
This work is not a peer-reviewed publication.  The Master’s Candidate author of this 
work has made every effort to provide accurate information and to rely on authoritative 
sources in the completion of this work.  However, neither the author nor the faculty 
advisor(s) warrants the completeness, accuracy or usefulness of the information provided 
in this work.  This work should not be considered authoritative or comprehensive in and 
of itself and the author and advisor(s) disclaim all responsibility for the results obtained 
from use of the information contained in this work.  Knowledge and practice change 
constantly, and readers are advised to confirm the information found in this work with 
other more current and/or comprehensive sources. 
 
The student author attests that this work is completely his/her original authorship and that 
no material in this work has been plagiarized, fabricated or incorrectly attributed.         
 
1 
 
The Effect of Testosterone Therapy on the Mortality Rate in 
Men Suffering From Diabetes Mellitus 
 
  
 
 
 
 
 
 
 
Deion Tran 
 
 
 
 
 
 
 
 
 
A Clinical Graduate Project Submitted to the Faculty of the 
School of Physician Assistant Studies 
Pacific University 
Hillsboro, OR 
For the Masters of Science Degree, August 8, 2015 
 
Faculty Advisor: Saje Davis-Risen, PA-C, MS 
Clinical Graduate Project Coordinator: Annjanette Sommers, PA-C, MS 
  
2 
 
Biography 
 
[Redacted for privacy]  
3 
 
Abstract 
 
Background: Low testosterone level is common with aging men and is associated with many 
adverse outcomes like diabetes mellitus (DM). In addition, men with low testosterone and DM 
have increased mortality risk. This review looks at the effect of testosterone therapy on mortality 
in men suffering from DM.  
 
Methods: An exhaustive literature search of available databases using Medline-OVID, CINAHL 
and Web of Science was conducted using the following keywords: testosterone, diabetes 
mellitus, and mortality.  
 
Results: The initial search of the databases yielded 58 articles. A total of two articles, both 
observation studies, met the inclusion criteria. The articles demonstrated decreased mortality rate 
in treated men with low testosterone suffering from DM.  
 
Conclusion: In both observation studies, testosterone therapy is associated with decreased 
mortality rate in men with DM. However, due to the studies’ limitations, further studies are 
needed to confirm the data.  
 
Keywords:  Testosterone, mortality, diabetes mellitus, therapy. 
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The Effect of Testosterone Therapy on the Mortality Rate in Men Suffering From 
Diabetes Mellitus 
 
BACKGROUND 
 Testosterone is one of the important hormones in the body. It maintains bone density, fat 
distribution, muscle strength and mass, red blood cells production, sex drive, and sperm 
production.1 A decline in testosterone level is common with aging men. As a result, diabetes, 
obesity, cardiovascular events, sarcopenia, osteoporosis, or a decreased libido occurs.2,3 A study4 
had noted mortality rate in men with low testosterone levels is double compared to men with 
normal testosterone levels. A low testosterone level in men is defined as total testosterone < 300 
ng/dl (10.4 nmol/L).5 Several studies6-8 have noted that low testosterone levels are associated 
with increase mortality risk in men with diabetes mellitus (DM). In addition, there is evidence 
demonstrating an increased occurrence of low testosterone in men with DM type 2,8-10 and a 
longitudinal cohort study11 found there is an increase in mortality associated with low 
testosterone in men with DM type 2. However, the direct link between low testosterone and DM 
is unknown.12 
Since 2000, testosterone therapy prescriptions have increased astronomically from 700 
000 per year to 2 700 000 in 2008.13 Some studies14-17 have shown the benefit of testosterone 
therapy such as increasing strength, muscle mass, bone mineral density, insulin sensitivity, and 
libido. In a large, multi-centre, randomized, double-blind, placebo-controlled study18 testosterone 
therapy was shown to improve insulin resistance, cholesterol, lipoprotein, body fat composition, 
sexual dysfunction in men with DM type 2. A meta-analysis19 of testosterone therapy trial on 
men with DM showed no increase of cardiovascular events in the treatment group; however, they 
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did not measure mortality. Can testosterone therapy have an effect on the mortality rate in men 
suffering from DM?  
METHODS 
 An exhaustive literature search of available databases using Medline-OVID, CINAHL 
and Web of Science was performed using the following keywords: testosterone, DM, and 
mortality. In both Medline-OVID and CINAHL, no further eligibility criteria were used. In Web 
of Science, the result was narrowed down using years 2000 to 2014, articles only, English-
language only, and endocrinology. The bibliographies of the articles were then screened by 
relevance. All articles that contained discussion of testosterone therapy and mortality were 
included. Relevant studies were assessed for quality using the Grading of Recommendations, 
Assessment, Development, and Evaluation (GRADE) criteria.20 
RESULTS 
 The initial search of Medline-OVID, CINAHL, and Web of Science yield 4, 18, and 36 
articles, respectively. After screening for relevance, a total of two articles met the inclusion 
criteria. These articles included one prospective cohort study5 and one retrospective cohort 
study.11 
Muraleedharan et al 
 In this prospective cohort study,5 the authors compared the mortality rate associated with 
testosterone therapy in men with DM type 2 to men that did not receive testosterone therapy with 
the same conditions. This study included patients that were recruited by district-wide diabetic 
retinopathy screening, in a hospital diabetic clinic, through the general community, or through a 
hospital database identifying DM type 2 patients. Of the 591 patients with DM type 2 who had 
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testosterone screened from 2002 to 2005, 238 patients were identified to have low testosterone. 
Low testosterone level is defined as total testosterone < 10.4 nmol/L. Of the 238 patients with 
low testosterone, 64 received testosterone therapy and 174 did not. The 174 patients did not 
receive testosterone therapy for following reasons: patient choice, declined to attend for further 
clinical assessment, did not response to invitation, or declined treatment. The authors noted that 
testosterone therapy is mainly administered to patient with total testosterone level < 8.4 nmol/L, 
without prostate cancer or other contraindication for testosterone therapy.5 
 The treatment group received either testosterone gel or testosterone intramuscularly (IM). 
Of the 64 patients, 55 received testosterone gel and 9 received testosterone IM. Doses were 
adjusted to achieve testosterone levels within the mid to upper normal range. The average 
duration of treatments was 41.6±20.7 (S.D.) months with 60 patients receiving testosterone 
therapy for ≥ 12 months and 51 patients receiving testosterone therapy ≥ 2 years. There was no 
significant differences in baseline characteristics between the normal testosterone group and low 
testosterone group. A follow-up was performed on average, 5.8±1.3 (S.D.) years later.5 
 The mortality rate was significantly higher in the untreated group (20.11%) compared to 
the treated group (9.38%).  The authors used the Kaplan-Meier curves which showed improved 
survival rate in the treated group compared with the untreated group. The authors also used the 
multivariate-adjusted survival curves in the Cox regression model, which showed the hazard 
ratio (HR) for decreased survival for the untreated group was 2.3; 95% CI 1.3-3.9; P=0.004.5 
 The authors noted that several meta-analyses have not found any increase in 
cardiovascular events with testosterone therapy.19,21-23 They concluded that long-term 
testosterone therapy is safe and there was a decreased mortality rate in men with low testosterone 
and DM type 2. In addition, the authors encouraged careful monitoring of testosterone levels 
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(also hematocrit and prostate specific antigen) when administering testosterone therapy with 
cautious dosing while achieving normal healthy range.5 
Shores et al 
 In this observational, retrospective cohort study,11 the authors examine the influence of 
testosterone therapy on mortality in men with low testosterone and whether results were 
modified by other factors such as DM. This study used the Veterans Affairs (VA) medical 
database, Consumer Health Information and Performance Set, to identify veteran men age > 40 
years old who had received treatment at the seven VA medical centers in the Northwest states 
and had total testosterone ≤ 250 ng/d (8.7 nmol/L) between January 1, 2001 to December 31, 
2002. Of the 5714 patients who had testosterone levels checked, 1090 patients were included in 
the final study. Of these final group, 393 patients with DM received testosterone therapy and 638 
patients did not received treatment.11 
 The primary focus of this study was mortality. The number of patients who died was 
obtained from the VA Beneficiary Identification records Locator Subsystem-Death File and the 
Social Security Administration-Death Master File. The Kaplan-Meier survival curves were used 
to show unadjusted survival times for the treated group compared to the untreated group. The HR 
and CI were calculated based on multivariate-adjusted survival curves in the Cox regression 
model.11 
 In the treatment group, 88.6% received testosterone IM, 9.1% used the testosterone patch, 
and 2.3% received testosterone gel which resulted in 398 patients who were treated with 
testosterone. The average duration of treatment was 20.2 months. The patients in this group were 
younger, had lower testosterone levels, and higher BMI compared to the untreated group; 
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otherwise, both groups are similar in the baseline characteristics. The average follow-up was 
42.8 months with 51 patients lost to follow-up.11 
 In the unadjusted analyses, the mortality rate is significantly higher in the untreated group 
- 20.7% compared to 10.3% in the treated group. In the unadjusted Kaplan-Meier survival curves 
shown, survival rate in the treated group was better compared to the untreated group (p = 0.029). 
In the time-varying Cox-adjusted regression model, there was a 39% reduction in mortality risk 
(HR 0.61, 95% CI 0.42-0.88, P = 0.008) in the treated group compared to untreated group. When 
analyzing the mortality rate in the treated group compared to untreated group by DM, there is an 
association with improve survival in men with DM received testosterone therapy. The HR for 
treated group with DM was 0.44; 95% CI 0.23-0.84; P=0.013 compared to the untreated with 
DM, HR 0.72; 95% CI 0.46-1.13; P=0.155.11 
 As a results of a lower HR in the treated group with DM compared to untreated men with 
DM, the authors concluded that testosterone therapy is associated with improved survival in men 
with low testosterone and DM. However, because this is the first study to examining the 
association between testosterone therapy and mortality in men with low testosterone levels, and 
this is an observational study, the authors caution readers to interpret the results cautiously.11 
 
DISCUSSION 
 In men, low testosterone is commonly associated with many adverse outcomes such as 
DM. In addition, men with DM has significant lower testosterone levels than those without 
DM.24 The link between those two conditions are unknown, but these men are at increasing risk 
of mortality when they are combined. There has been increased use of testosterone therapy since 
2000 which has shown to improve strength, muscle mass, bone mineral density, insulin 
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sensitivity, and libido.14-17 However, there have been no studies on mortality until two studies in 
the Muraleedharan et al5 and Shores et alto11 demonstrated increase survival rate in low 
testosterone men suffering from DM compared to men who did not received treatment. 
 Reviewing the two studies5,11 that compared testosterone treatment and mortality risk in 
men with DM it is clear that there is some correlation. In the Shores et al study,11 the authors 
demonstrated a decreased in mortality rate of men with DM who received testosterone therapy 
compared to men with the same condition and did not received treatment. The result can be seen 
in Table 1.11 In the Muraleedharan et al study,5 the authors demonstrated an increase in survival 
rate of low testosterone men with DM type 2 who received testosterone therapy compared to 
men with the same condition and did not received treatment.5 Furthermore, testosterone therapy 
has been shown to be safe when a patient has low levels.19 
 Although these two studies showed the benefit of testosterone therapy in men with low 
testosterone and DM, there are limitations in both studies. These two studies were evaluated 
using the GRADE method and the results can be seen in Table 1. Both studies5,11 were of 
observational study design. Moreover, both used a lower testosterone thresholds in treated 
patients. In the Shores et al study,11 treated patients had total testosterone levels of 8.7 nmol/L 
compared to the treated patient in the Muraleedharan et al study5 who had an average total 
testosterone level of 6.8±2.3 nmol/L. This could lead to overestimating the treatment effects, 
thus, limiting the interpretation of the results. 
 Another limitation, mainly from the Shores et al study,11 is that patients were initiated 
into testosterone therapy based on one testosterone level check instead of the recommended two 
testosterone level checks from the clinical guideline. It is recommended to recheck the 
testosterone level because lower testosterone level can be due to serious conditions like 
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cardiovascular diseases or DM.25 Lastly, the study11 contains patients with history of high risk of 
chronic medical morbidity including coronary heart disease and diabetes. The generalizability of 
the results are, therefore, limited. 
 Because of these limitations, larger and longer studies with double-blind, placebo-
controlled design will increase confidence of whether or not mortality risk is improved in men 
with DM who also have low testosterone. 
CONCLUSION 
 Testosterone therapy has shown to decrease mortality rate in men suffering from DM in 
two observation studies. However, due to these studies’ limitations, the results should be 
cautiously interpreted but testosterone therapy may be beneficial in the long-term in improving 
survival rate in men with low testosterone and DM. A further long-term and large randomized 
controlled trial is needed to confirm this data. 
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Table I. Characteristics of Reviewed Studies and Summary of Findings 
 
a Studies were upgraded due to large treatment effect  
 
 
 
 
 
 
Quality Assessment 
Treatment Effect 
Quality Downgrade Criteria 
Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
HR 
(95% CI) 
RR NNT 
Muraleedharan et al5 
Prospective 
cohort 
 No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies No bias likely 
2.3 
(1.3-3.9) 
0.47 
10 Moderatea RRR 
0.53 
Shores et al11 
Retrospective 
cohort 
No serous 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies No bias likely 
0.61 
(0.42-0.88) 
0.50 
10 Moderatea RRR 
0.50 
